Rising hunger, waist growth, weight gain above about 2 lb per month, persistent heart-rate elevation, or declining strength indicate that the lower dose is not maintaining the prior response
Ann Nutr Metab 75(4):205212
Importantly, semaglutidetreated patients experienced sustained weight loss (mean ~10.2% vs 1.5% at 208 weeks) and improvements in waist circumference and waisttoheight ratio, anthropometric changes that track with cardiometabolic risk reduction
In an OASIS-1 clinical trial , people who took 50 mg of oral semaglutide daily lost an average of 15.1% of their body weight after 68 weeks (about a year and four months)
Unlike sedative medications, DSIP is a sleep-promoting peptide, meaning it helps to normalize sleep patterns without causing grogginess or building up a tolerance
-How can I use carnitine with existing carbohydrate loading protocols